Src like adaptor 2Genealiases: C20orf156 · MARS · SLAP-2 · SLAP2
Q-omics provides the consensus-scored SLA2 profile across patient tissues and cancer cell-line models. SLA2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, SLA2 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, SLA2 RNA expression shows 17,090 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight SKCM, KIRC, and DLBC as cancer lineages where SLA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLA2 survival associations across molecular data types. SLA2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLA2 RNA expression–survival associations across cancer types. High SLA2 expression shows unfavorable associations in UVM, but favorable associations in SKCM, HNSC, CESC, UCEC and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for SLA2 RNA expression.
This table summarizes SLA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SLA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLA2 shows lower tumor expression in COAD and LUSC and higher tumor expression in KIRC, KIRP, STAD and BRCA. The KIRC box plot shows higher SLA2 RNA expression in tumor versus normal tissue (log2 FC = +1.939, t-test p < 0.001).
This table shows molecular features associated with SLA2 in patient tissues and cancer cell lines. In patient samples, SLA2 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set. In cancer cell lines, SLA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
